AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29516257 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA10 (10 J cm(2) for 15 min)
Number of subjects: 10
Study 29516257 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA20 (20 J cm(2) for 30 min)
Number of subjects: 10
Study 29516257 — intervention group
Group type: COMPARATOR
Intervention: CON (no light)
Number of subjects: 10
Study 27484673 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm laser treatment
Number of subjects: 11
Study 27484673 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study 24953021 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 64
Study 24953021 — intervention group
Group type: COMPARATOR
Intervention: Variceal Band Ligation (VBL)
Number of subjects: 64
Study 22446517 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional weekend physical therapy (PT) and occupational therapy (OT)
Number of subjects: 105
Study 22446517 — intervention group
Group type: COMPARATOR
Intervention: Control group received PT and OT Monday to Friday
Number of subjects: 105
Study 20429041 — intervention group
Group type: EXPERIMENTAL
Intervention: General internists
Number of subjects: 0
Study 20429041 — intervention group
Group type: COMPARATOR
Intervention: IM subspecialists
Number of subjects: 0
Study 18758197 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyContin tablets (controlled‐release oxycodone hydrochloride: 5, 10, 20, and 40 mg)
Number of subjects: 0
Study 18758197 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyContin tablets
Number of subjects: 0
Study 15968406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (200 IU per kilogram subcutaneously daily)
Number of subjects: 24
Study 15968406 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 12964131 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (six sessions)
Number of subjects: 108
Study 10592923 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Language Impairment group (SLI)
Number of subjects: 33
Study 10592923 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 8758083 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CHL) 25 mg/kg over 3 days
Number of subjects: 0
Study 8758083 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine (SDX) 25 mg/kg plus Pyrimethamine (PYR) 1.25 mg/kg (statim dose)
Number of subjects: 0
Study 1916791 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon (IFN) alpha 2a plus cryotherapy
Number of subjects: 60
Study 1916791 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections plus cryotherapy
Number of subjects: 60
Study 6123343 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride (200 mg)
Number of subjects: 0
Study 6123343 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 0
Study 31744837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 63276
Study 31744837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) with longer time (>4 years) since initiation
Number of subjects: 63276
Study 31744837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) with higher mean daily dose (>1000 μg fluticasone equivalents)
Number of subjects: 63276
Study 31744837 — intervention group
Group type: COMPARATOR
Intervention: No ICS use
Number of subjects: 63276
Study 31436190 — intervention group
Group type: COMPARATOR
Intervention: PPV with no ILM peeling
Number of subjects: 287
Study 31436190 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with macular peeling
Number of subjects: 287
Study 31436190 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with macular plus peripapillary peeling
Number of subjects: 287
Study 27797683 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 500 mg daily for 4 weeks
Number of subjects: 20
Study 27797683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26029855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (3 g per day, 1 g before each meal) with a low-calorie diet
Number of subjects: 90
Study 21959840 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive (MIS) multilevel hemilaminectomy
Number of subjects: 54
Study 21959840 — intervention group
Group type: COMPARATOR
Intervention: Open multilevel hemilaminectomy
Number of subjects: 54
Study 21442805 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture intervention in the observation group (48 cases)
Number of subjects: 68
Study 21442805 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in the control group (20 cases)
Number of subjects: 68
Study 19364625 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-led appointments
Number of subjects: 23
Study 19364625 — intervention group
Group type: COMPARATOR
Intervention: Recruiter-led appointments
Number of subjects: 23
Study 19364625 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication techniques (open questions, pauses, ceding the floor)
Number of subjects: 23
Study 16802291 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (800 mg/day)
Number of subjects: 300
Study 16802291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 15578632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine test formulation from Apotex do Brasil, 250 mg dose
Number of subjects: 0
Study 15578632 — intervention group
Group type: COMPARATOR
Intervention: Ticlid from Sanofi‐Synthelabo, 250 mg dose
Number of subjects: 0
Study 11386398 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps training
Number of subjects: 80
Study 9390588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 0.5 mg
Number of subjects: 106
Study 9390588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 1 mg
Number of subjects: 106
Study 9390588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 2 mg
Number of subjects: 106
Study 9390588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 4 mg
Number of subjects: 106
Study 9390588 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 106
Study 7910722 — intervention group
Group type: EXPERIMENTAL
Intervention: GLQ223 administered intravenously at doses of 36 and 50 micrograms/kg
Number of subjects: 22
Study 7910722 — intervention group
Group type: EXPERIMENTAL
Intervention: GLQ223 administered intravenously at doses of 8, 16, 24, 36, and 50 micrograms/kg
Number of subjects: 22
Study 7910722 — intervention group
Group type: EXPERIMENTAL
Intervention: GLQ223 administered intravenously
Number of subjects: 22
Study 3332564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 47
Study 3332564 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 47
Study 3332564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31711134 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive HTE analysis using risk-modeling approach
Number of subjects: 0
Study 31711134 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive HTE analysis using effect-modeling approach
Number of subjects: 0
Study 31711134 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-modeling approaches
Number of subjects: 0
Study 31711134 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect-modeling approaches
Number of subjects: 0
Study 31578080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) lowering by 50 mg/dL (105 nmol/L) for 5 years
Number of subjects: 2527
Study 31578080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) lowering by 99 mg/dL (212 nmol/L) for 5 years
Number of subjects: 2527
Study 31578080 — intervention group
Group type: COMPARATOR
Intervention: Individuals with Lp(a)<10 mg/dL (18 nmol/L)
Number of subjects: 2527
Study 31578080 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Lp(a) 10 to 49 mg/dL (18-104 nmol/L)
Number of subjects: 2527
Study 31578080 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Lp(a) 50 to 99 mg/dL (105-213 nmol/L)
Number of subjects: 2527
Study 31578080 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Lp(a) ≥100 mg/dL (≥214 nmol/L)
Number of subjects: 2527
Study 26554107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl rapide
Number of subjects: 96
Study 26554107 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut
Number of subjects: 96
Study 26554107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexon
Number of subjects: 96
Study 26554107 — intervention group
Group type: COMPARATOR
Intervention: All three groups (Vicryl rapide, Catgut, Dexon)
Number of subjects: 96
Study 24077867 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking plate
Number of subjects: 52
Study 24077867 — intervention group
Group type: COMPARATOR
Intervention: Non-locking plate
Number of subjects: 52
Study 21712481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (10 mg oral) administered 2 days per week before physiotherapy
Number of subjects: 16
Study 21712481 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 2 days per week before physiotherapy
Number of subjects: 16
Study 19012955 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 12306
Study 16919578 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial oxidative metabolism (kmono) in NIDCM patients
Number of subjects: 7
Study 16919578 — intervention group
Group type: COMPARATOR
Intervention: Myocardial oxidative metabolism (kmono) in normal subjects
Number of subjects: 7
Study 16919578 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-pressure product (RPP) in NIDCM patients
Number of subjects: 7
Study 16919578 — intervention group
Group type: COMPARATOR
Intervention: Rate-pressure product (RPP) in normal subjects
Number of subjects: 7
Study 16919578 — intervention group
Group type: EXPERIMENTAL
Intervention: kmono/RPP ratio in NIDCM patients
Number of subjects: 7
Study 16919578 — intervention group
Group type: COMPARATOR
Intervention: kmono/RPP ratio in normal subjects
Number of subjects: 7
Study 14586387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Number of subjects: 12
Study 14586387 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Number of subjects: 12
Study 14586387 — intervention group
Group type: COMPARATOR
Intervention: Air breathing (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Number of subjects: 12
Study 10740559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg pretreatment
Number of subjects: 90
Study 10740559 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment (Control)
Number of subjects: 90
Study 10740559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg pretreatment
Number of subjects: 90
Study 9176539 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100, 200, and 400 micrograms
Number of subjects: 14
Study 9176539 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 600, 1200, and 2400 micrograms
Number of subjects: 14
Study 9176539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8471369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial technique with 1% mepivacaine 45 ml with adrenaline
Number of subjects: 50
Study 8471369 — intervention group
Group type: COMPARATOR
Intervention: Perivascular technique with 1% mepivacaine 45 ml with adrenaline
Number of subjects: 50
Study 8471369 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography after contrast medium added to 0.5% bupivacaine 40 ml
Number of subjects: 50
Study 8471369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (perivascular and transarterial)
Number of subjects: 50
Study 3535687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride
Number of subjects: 81
Study 3535687 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate
Number of subjects: 81
Study 31806099 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d for 3 months
Number of subjects: 48
Study 31806099 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 3 months
Number of subjects: 48
Study 31806099 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d for 3 months (after initial no treatment)
Number of subjects: 48
Study 29773846 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for appetite
Number of subjects: 193
Study 29773846 — intervention group
Group type: EXPERIMENTAL
Intervention: Days spent in acute hospital post-ICU
Number of subjects: 193
Study 29773846 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum C-reactive protein (CRP) concentration
Number of subjects: 193
Study 26581199 — intervention group
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 combined with AS15 immunostimulant administered intramuscularly (group A, n=13)
Number of subjects: 25
Study 26581199 — intervention group
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 combined with AS15 immunostimulant administered intradermally/subcutaneously (group B, n=12)
Number of subjects: 25
Study 26581199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of immunization (i.m. and i.d./s.c.)
Number of subjects: 25
Study 24814583 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative selective decontamination of the digestive tract (SDD) with colistin, tobramycin, and amphotericin B in addition to standard antibiotic prophylaxis
Number of subjects: 762
Study 24814583 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic prophylaxis alone
Number of subjects: 762
Study 22284330 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal balloon occlusion
Number of subjects: 62
Study 22284330 — intervention group
Group type: COMPARATOR
Intervention: Filter protection
Number of subjects: 62
Study 19608584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum strategy (SS)
Number of subjects: 20
Study 19608584 — intervention group
Group type: COMPARATOR
Intervention: Clinical strategy (CS)
Number of subjects: 20
Study 18280560 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone dietary counseling
Number of subjects: 74
Study 18280560 — intervention group
Group type: COMPARATOR
Intervention: Standardized, written nutritional information
Number of subjects: 74
Study 15877297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortitrol supplementation
Number of subjects: 0
Study 12665398 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (mean 274.2 mg/day)
Number of subjects: 490
Study 12665398 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (mean 16.6 mg/day)
Number of subjects: 490
Study 10232630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) group
Number of subjects: 27
Study 10232630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis-related diabetes mellitus (CFDM) group
Number of subjects: 27
Study 10232630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 8826973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h insulin levels in individuals who developed NIDDM
Number of subjects: 838
Study 8826973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean 2-h insulin concentration changes
Number of subjects: 838
Study 8826973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin levels
Number of subjects: 838
Study 8826973 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fasting and 2-h glucose concentrations
Number of subjects: 838
Study 8826973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and 2-h insulin concentrations
Number of subjects: 838
Study 8826973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and 2-h glucose levels
Number of subjects: 838
Study 8826973 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 838
Study 8826973 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels
Number of subjects: 838
Study 8391072 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 8391072 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 8391072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3105368 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin ointment
Number of subjects: 34
Study 3105368 — intervention group
Group type: COMPARATOR
Intervention: Bland ointment
Number of subjects: 34
Study 29191442 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumpatellar electrocautery plus patellar resurfacing
Number of subjects: 53
Study 29191442 — intervention group
Group type: COMPARATOR
Intervention: Circumpatellar electrocautery only
Number of subjects: 53
Study 27131044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cine-derived dyscontractility index (CDI)
Number of subjects: 52
Study 27131044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cine-derived indices
Number of subjects: 52
Study 27131044 — intervention group
Group type: COMPARATOR
Intervention: tMRI-based indices
Number of subjects: 52
Study 25668345 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 24
Study 25668345 — intervention group
Group type: COMPARATOR
Intervention: High sodium intake
Number of subjects: 24
Study 22725990 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcrestal balloon technique (B)
Number of subjects: 10
Study 22725990 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteotome approach (C)
Number of subjects: 10
Study 20151940 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and vitamin A supplementation (10 mg elemental zinc per day and one-half of a 25,000 IU vitamin A tablet every other day)
Number of subjects: 48
Study 20151940 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and vitamin A supplementation
Number of subjects: 48
Study 20151940 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 48
Study 19177660 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy exercises 'Brain gymnastics' (n = 41)
Number of subjects: 83
Study 19177660 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitative treatment (n = 41)
Number of subjects: 83
Study 16886964 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 30
Study 16886964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12648639 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1a (primary posterior capsulotomy and anterior vitrectomy)
Number of subjects: 34
Study 12648639 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1b (optic capture in addition)
Number of subjects: 34
Study 12648639 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2a (primary posterior capsulotomy without anterior vitrectomy)
Number of subjects: 34
Study 12648639 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2b (optic capture in addition)
Number of subjects: 34
Study 12648639 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2c (in-the-bag IOL implantation without opening the posterior capsule)
Number of subjects: 34
Study 12648639 — intervention group
Group type: COMPARATOR
Intervention: Eyes that developed PCO
Number of subjects: 34
Study 10401799 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula with sucrose
Number of subjects: 200
Study 10401799 — intervention group
Group type: COMPARATOR
Intervention: Soy-based formula with lactose
Number of subjects: 200
Study 7854859 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin
Number of subjects: 10
Study 7854859 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin
Number of subjects: 10
Study 2811556 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous dexamethasone before the procedure
Number of subjects: 30
Study 2811556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1108720 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of terbutaline
Number of subjects: 5
Study 1108720 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of metaproterenol
Number of subjects: 5
Study 1108720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31712211 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC lock solution with taurolidine‐citrate‐heparin
Number of subjects: 150
Study 31712211 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (placebo)
Number of subjects: 150
Study 30778572 — intervention group
Group type: EXPERIMENTAL
Intervention: L-OTM (equivalent to L-ITM)
Number of subjects: 600
Study 30778572 — intervention group
Group type: COMPARATOR
Intervention: COM (commercial levels of inorganic minerals)
Number of subjects: 600
Study 30778572 — intervention group
Group type: EXPERIMENTAL
Intervention: COM and OTM
Number of subjects: 600
Study 30778572 — intervention group
Group type: EXPERIMENTAL
Intervention: L-OTM
Number of subjects: 600
Study 30778572 — intervention group
Group type: EXPERIMENTAL
Intervention: COM, L-OTM, and OTM
Number of subjects: 600
Study 28642810 — intervention group
Group type: EXPERIMENTAL
Intervention: low-amount/moderate-intensity (10KKW/50%) exercise
Number of subjects: 169
Study 28642810 — intervention group
Group type: EXPERIMENTAL
Intervention: high-amount/moderate-intensity (16KKW/50%) exercise
Number of subjects: 169
Study 28642810 — intervention group
Group type: EXPERIMENTAL
Intervention: high-amount/vigorous-intensity (16KKW/75%) exercise
Number of subjects: 169
Study 28642810 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Lifestyle (combined diet plus low-amount/moderate-intensity exercise) intervention
Number of subjects: 169
Study 28642810 — intervention group
Group type: COMPARATOR
Intervention: All four interventions combined
Number of subjects: 169
Study 25820066 — intervention group
Group type: EXPERIMENTAL
Intervention: AVA vaccine
Number of subjects: 0
Study 25820066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24517059 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Jinhua Qinggan Granule (10 g each time, 3 times daily for 5 days)
Number of subjects: 136
Study 24517059 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Jinhua Qinggan Granule (5 g JHG + 5 g placebo each time, 3 times daily for 5 days)
Number of subjects: 136